Developing story: the committee will meet in private to decide how to proceed. No timeline for the forensic investigation has been given.

MPs on Parliament's health portfolio committee on Wednesday accused the Department of Health of failing to act a month after the High Court set aside a R15 billion contract for anti-retroviral (ARV) drugs. Health Minister Aaron Motsoaledi told the committee a forensic investigation will be carried out.

What the committee heard

The High Court set the tender aside in October 2026. Cipla and Hetero Drugs South Africa, both unsuccessful bidders, brought the application against the award.

Committee chairperson Faith Muthambi said it was unacceptable that no consequence management had followed a month after the ruling. She asked for the names of everyone who served on the bid evaluation and bid adjudication committees, and said some of the officials under scrutiny could be in the meeting. Addressing newly appointed Director-General Thembisile Xulu, she said: "By now you should have acted."

EFF MP Naledi Chirwa said Motsoaledi should have acted months earlier. She said the committee warned him on 18 February and he did nothing.

ActionSA MP Tebogo Letlape called for a commission of inquiry into health tenders to examine collusion and anti-competitive conduct among pharmaceutical companies.

The minister's response

Motsoaledi said he cannot get directly involved in procurement matters and that a forensic investigation would be conducted. He said former Director-General Sandile Buthelezi should not have signed off on the ARV contracts after the two bid committees gave him conflicting information.

Buthelezi was arrested by the Hawks in March 2026 in a separate tender matter. He is presumed innocent unless a court finds otherwise.

What happens next

Angered by the responses, the committee resolved to meet in private to decide how to proceed.

What we do not yet know

  • Which companies hold the contracts that were set aside, and what the contract terms are.
  • When the forensic investigation will start and who will lead it.
  • Whether the department will appeal the court ruling or re-run the tender, and how patients' supply of ARV drugs will be secured in the meantime.